Nutra Pharma has announced that it has completed the first commercial production run of its pain drug, Cobroxin, and has successfully released it for distribution to XenaCare Holdings. The company expects Cobroxin to be available for sale as early as October 10th.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

“We are excited to have successfully completed the first commercial production run of Cobroxin and to have passed all quality control assays,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Because this process was completed early and we have already signed off for final distribution to XenaCare Holdings, we anticipate that Cobroxin will be available for sale as early as October 10th,” he added.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Recently, Nutra Pharma announced a licensing agreement with XenaCare Holdings, which grants XenaCare the exclusive marketing and distribution rights for Cobroxin in the United States. Additionally, the company announced its intentions to begin the registration process in Canada and Europe.